

ASX Announcement

EQiTX Board Changes

26 July 2005, Melbourne: The Board of Directors of EQiTX Limited (ASX:EQX) announced today that the Perth based directors Mr Brian Nathanson and Mr Geoff Harland had tendered their resignations from the EQiTX Board with effect from 31 July 2005.

Their decision is in keeping with the company having relocated its corporate and administrative offices to Melbourne, where management and operations are now based.

Brian Nathanson has been a director of EQiTX since July 2003. In this role he has in particular been responsible for investor relations and capital raisings and has also been a Member of the Audit Committee. "We will miss Brian's business acumen and enthusiasm and thank him for his guidance and contribution over the past 2 years" said Mr Sol Majteles, Chairman of EQiTX. "Brian was instrumental as a founding shareholder in the creation of EQiTX and through his later Board involvement, has enabled it to become the biotechnology investment and management company that it is today" he added.

Geoff Harland has been a Director of EQiTX since December 2001. He has been responsible at Board level for implementation of the Corporate Governance Charter and has also served as Chairman of the Audit Committee. "We thank Geoff for his important contributions and for the input and support he has provided to the Board and management over this time" added Mr Majteles.

"We wish both Brian and Geoff every success with their future endeavours and thank them for their contribution and support of management over the years" said Ms Sue MacLeman, CEO of EQiTX.

EQiTX will now move forward with a more streamlined Board in readiness for the next phase of the company's growth and development.

Inquiries:

Sue MacLeman
Chief Executive Officer
EQiTX Limited
0437 211 200

Rudi Michelson
(Monsoon Communications)
0411 402 737

About EQiTX (www.EQiTX.com)

EQiTX Limited (ASX:EQX) is a publicly listed Australian biotechnology company with interests in the areas of chronic diseases and age-related conditions. EQiTX is developing a portfolio of technologies to a stage where they will be of commercial interest to multinational pharmaceutical and biotechnology companies. The company's two main programs are: the ZingoTX project to develop pharmacologically active compounds for pain management; and the VacTX project to develop and commercialise novel synthetic immunotherapeutics against a range of human conditions, including infectious diseases, cancer, allergies and autoimmune diseases.

EQiTX Limited

Level 1, 123 Camberwell Rd
Hawthorn East VIC 3123,
Phone (+61 3) 98119998
Fax: (+61 3) 98134259

Email: info@eqitx.com
www.eqitx.com

ABN: 50 009 188 694